References
- Espin J, Oliva J, Rodríguez Barrios JM. Esquemas de mejora de acceso al mercado de nuevas tecnologías: los acuerdos de riesgo compartido. Gac Sanit 2010;24:491-7
- Carlson J, Sullivan S, Garrison L, et al. Linking payment of health outcomes: a taxonomy and examination of performance based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010;96:179-90
- Newman PJ, Chambers JD, Simon F, et al. Risk sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Affairs 2011;30:2329-37
- Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010;10:153
- Pugatch M, Healy P, Chu R. Sharing the burden: could risk sharing change the way we pay for healthcare? Available at: http://www.stockholm-network.org/downloads/publications/Sharing_the_Burden.pdf [Last accessed 15 May 2015]
- Towse A. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Br J Clin Pharmacol 2010;70:360-6
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin – paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
- Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
- Maemodo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
- Institut Catalá d´Oncología. ICO Praxis para el tratamiento médico y con irradiación del cáncer de pulmón célula no pequeña. Barcelona: Generalitat de Cataluña, Departament de Salut, 2011. Available at: http://ico.gencat.cat/web/.content/minisite/ico/professionals/documents/arxius/icoprax__cpcnp_cast_def.pdf [Last accessed 7 September 2014]
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Canc 2009;45:228-47
- General Council of the Association of Official Pharmacists. General Council of the Association of Official Pharmacists Database: Bot PLUS 2.0. Available at: https://botplusweb.portalfarma.com/ [Last acessed 21 June 2016]
- Garrison LP, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements – good practices for design, implementation, and evaluation: report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. Value Health 2013;16:703-19
- Douilard J-Y, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Canc 2014;110:55-62
- Navarria A, Drago V, Gozzo L et al. Do the current performance-based schemes in Italy really work? “Success Fee”: a novel measure for cost-containment of drug expenditure. Value Health 2015;18:131-6
- van de Vooren K, Curto A, Freemantle N, Garattini L. Market access agreements for anti-cancer drugs. J R Soc Med 2015;108:166-170
- British Oncology Pharmacy. A report into the uptake of patient access schemes (PAS) in the NHS. Available at: http://www.bopawebsite.org/contentimages/publications/Report_into_Uptake_of_Patient_Access_Schemes_8_11_09.pdf [Last accessed 27 October 2014]
- Haynes S, Timm B, Hamerslag L, Wong Grand Costello S. The administrative burden of patient access schemes in the changing UK healthcare system: a follow up study. Available at: http://www.costellomedical.com/wp-content/uploads/2014/03/Madrid_Poster_PHP1521.pdf [Last acessed 22 April 2015]
- Garattini L, Casadei G. Risk sharing agreements: what lessons from Italy? Int J Technol Assess Health Care 2011;27:169-72
- Garattini L, Curto A, van de Vooren. Italian risk-sharing agreements on drugs: are they worthwhile. Eur J Health Econ 2015;16:1-3
- Segú Tolsa JL, Puig-Junoy J, Espinosa Tomé C, coordinadores. Guía para la Definición de Criterios de Aplicación de Esquemas de Pago basados en Resultados (EPR) en el Ámbito Farmacoterapéutico (Acuerdos de Riesgo Compartido). Versión 1.0. Barcelona: Generalitat de Catalunya, Departament de Salut, Servei Catalá de la Salut (CatSalut), 2014